Gland Pharma Limited

BSE:543245 Stock Report

Market Cap: ₹286.3b

Gland Pharma Valuation

Is 543245 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543245 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 543245 (₹1739.1) is trading above our estimate of fair value (₹804.66)

Significantly Below Fair Value: 543245 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543245?

Key metric: As 543245 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543245. This is calculated by dividing 543245's market cap by their current earnings.
What is 543245's PE Ratio?
PE Ratio41.4x
Earnings₹6.92b
Market Cap₹286.34b

Price to Earnings Ratio vs Peers

How does 543245's PE Ratio compare to its peers?

The above table shows the PE ratio for 543245 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48x
506943 J. B. Chemicals & Pharmaceuticals
44.1x19.4%₹269.5b
AJANTPHARM Ajanta Pharma
43.1x16.4%₹377.5b
IPCALAB Ipca Laboratories
59.2x29.9%₹391.4b
EMCURE Emcure Pharmaceuticals
45.6x25.3%₹258.6b
543245 Gland Pharma
41.4x25.8%₹286.3b

Price-To-Earnings vs Peers: 543245 is good value based on its Price-To-Earnings Ratio (41.4x) compared to the peer average (48x).

Price to Earnings Ratio vs Industry

How does 543245's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.5xn/aUS$66.09m
524652 Ind-Swift
2xn/aUS$13.18m
No more companies available in this PE range
543245 41.4xIndustry Avg. 33.1xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 543245 is expensive based on its Price-To-Earnings Ratio (41.4x) compared to the Indian Pharmaceuticals industry average (33.1x).

Price to Earnings Ratio vs Fair Ratio

What is 543245's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543245 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41.4x
Fair PE Ratio46.6x

Price-To-Earnings vs Fair Ratio: 543245 is good value based on its Price-To-Earnings Ratio (41.4x) compared to the estimated Fair Price-To-Earnings Ratio (46.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 543245 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,739.10
₹1,813.25
+4.3%
26.6%₹3,120.00₹1,214.00n/a12
Nov ’25₹1,644.85
₹1,920.25
+16.7%
29.0%₹3,120.00₹1,214.00n/a12
Oct ’25₹1,799.90
₹1,942.75
+7.9%
29.5%₹3,120.00₹1,214.00n/a12
Sep ’25₹1,838.20
₹1,983.58
+7.9%
28.5%₹3,120.00₹1,214.00n/a12
Aug ’25₹2,122.15
₹1,886.58
-11.1%
29.0%₹3,120.00₹1,214.00n/a12
Jul ’25₹1,819.80
₹1,827.33
+0.4%
31.2%₹3,120.00₹873.00n/a12
Jun ’25₹1,839.15
₹1,827.33
-0.6%
31.2%₹3,120.00₹873.00n/a12
May ’25₹1,711.45
₹1,845.25
+7.8%
32.5%₹3,120.00₹873.00n/a12
Apr ’25₹1,815.40
₹1,861.58
+2.5%
30.7%₹3,120.00₹1,130.00n/a12
Mar ’25₹1,786.40
₹1,876.00
+5.0%
29.4%₹3,120.00₹1,130.00n/a13
Feb ’25₹1,983.85
₹1,756.67
-11.5%
31.2%₹3,120.00₹906.00n/a15
Jan ’25₹1,907.10
₹1,669.00
-12.5%
30.3%₹3,120.00₹871.00n/a15
Dec ’24₹1,807.45
₹1,649.00
-8.8%
30.1%₹3,120.00₹871.00n/a15
Nov ’24₹1,532.00
₹1,544.33
+0.8%
34.4%₹3,120.00₹871.00₹1,644.8515
Oct ’24₹1,674.90
₹1,477.67
-11.8%
35.0%₹3,120.00₹871.00₹1,799.9015
Sep ’24₹1,766.80
₹1,477.67
-16.4%
35.0%₹3,120.00₹871.00₹1,838.2015
Aug ’24₹1,301.10
₹1,428.80
+9.8%
38.7%₹3,120.00₹925.00₹2,122.1515
Jul ’24₹1,062.65
₹1,434.80
+35.0%
38.6%₹3,120.00₹925.00₹1,819.8015
Jun ’24₹932.15
₹1,445.44
+55.1%
39.0%₹3,120.00₹925.00₹1,839.1516
May ’24₹1,358.75
₹1,734.67
+27.7%
29.7%₹3,120.00₹1,200.00₹1,711.4515
Apr ’24₹1,268.60
₹1,771.33
+39.6%
28.8%₹3,120.00₹1,200.00₹1,815.4015
Mar ’24₹1,291.80
₹1,990.63
+54.1%
45.0%₹4,930.00₹1,300.00₹1,786.4016
Feb ’24₹1,263.05
₹2,118.88
+67.8%
42.3%₹4,930.00₹1,300.00₹1,983.8517
Jan ’24₹1,576.20
₹2,547.53
+61.6%
27.8%₹4,930.00₹1,660.00₹1,907.1017
Dec ’23₹1,752.50
₹2,538.28
+44.8%
26.9%₹4,930.00₹1,800.00₹1,807.4518
Nov ’23₹1,786.95
₹2,615.78
+46.4%
25.5%₹4,930.00₹1,920.00₹1,532.0018

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Colinz Laboratories

₹142.4m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.52

7D

2.7%

1Y

34.5%

Novartis India

₹26.9b

Operates as a healthcare company in India.

500672

₹1,090.30

7D

6.3%

1Y

54.5%